CRDF
Cardiff Oncology, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Cardiff Oncology (CRDF) Stock: Buy, Sell, or Hold?
$0.73
-0.04 (-4.93%)
▼
5d:
-3.67%
30d:
-25.25%
90d:
-24.44%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
43/100
Position
OVERSOLD
30-Day Fair Range
$0.81 – $1.02
Position: OVERSOLD
Forward P/E & Valuation
-1.4x
Next 12M consensus est.
Wall Street Target
$6.28
+763.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$0.72 / $0.92
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: CRDF shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When CRDF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: CRDF is currently trading at $0.73, which is considered oversold relative to its 30-day fair value range of $0.81 to $1.02.
Technical Outlook: Technically, CRDF is in a strong downtrend. The price is currently testing key support at $0.72. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: CRDF scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.28 (+763.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRDF is in a strong downtrend. The price is currently testing key support at $0.72. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: CRDF scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.28 (+763.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.81 -
$1.02
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Trading Range & Key Levels
30-Day Trading Range
$0.81 -
$1.02
Current vs Trading Range
OVERSOLD
Support Level
$0.72
Resistance Level
$0.92
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 763.6% below Wall St target ($6.28)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.36
Wall Street Target
$6.28
(+763.6%)
Revenue Growth (YoY)
-14.1%
Share CRDF Analysis
Share this live CRDF analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (CRDF)
Bearish
5 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
4 msgs
24h retail stream
Last Tracked
Nov 13, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits messages are bullish on $CRDF following Pfizer's ownership in Cardiff Oncology and the company's recent drug approval. The latest Yahoo Finance news article reports Revolution Medicines (similar company) saw a 6.4% stock decline in November 2026, despite FDA approval of their cancer drug Daraxonrasib, generating $198 million in net product revenue in the third quarter.
Key Retail Themes:
Company's drug approval
Revenue generated from the drug
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 5:34 AM ET
Data refreshes hourly during market hours. Next update: 6:34 AM
Data refreshes hourly during market hours. Next update: 6:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRDF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 37 SELL |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 58 HOLD |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive CRDF Research Pages
